NVS ▲ +3.5% - Novartis AG $NVS remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials Novartis shares gained 3.5% following positive Phase III trial results for remibrutinib, its oral BTK inhibitor candidate, which demonstrated significant reductions in relapse rates in relapsing multiple sclerosis patients alongside an acceptable safety profile. The favorable efficacy and safety data support the drug's development potential in a competitive MS treatment landscape. 01-SEP-2026 05:19 AM ET